Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Terns Pharmaceuticals (TERN) over the last 5 years, with Dec 2024 value amounting to -$89.6 million.

  • Terns Pharmaceuticals' Income towards Parent Company fell 31.27% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 49.01%. This contributed to the annual value of -$89.6 million for FY2024, which is 0.79% up from last year.
  • As of FY2024, Terns Pharmaceuticals' Income towards Parent Company stood at -$89.6 million, which was up 0.79% from -$90.3 million recorded in FY2023.
  • In the past 5 years, Terns Pharmaceuticals' Income towards Parent Company registered a high of -$41.8 million during FY2020, and its lowest value of -$90.3 million during FY2023.
  • Moreover, its 3-year median value for Income towards Parent Company was -$89.6 million (2024), whereas its average is -$80.1 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 49.01% in 2023, then grew by 0.79% in 2024.
  • Yearly analysis of 5 years shows Terns Pharmaceuticals' Income towards Parent Company stood at -$41.8 million in 2020, then fell by 20.33% to -$50.2 million in 2021, then dropped by 20.59% to -$60.6 million in 2022, then tumbled by 49.01% to -$90.3 million in 2023, then climbed by 0.79% to -$89.6 million in 2024.